Abstract
Assess the androgenic block in prostate cancer as metabolic syndrome cause and as arterial coronary disease risk factor, besides to determinate the outline of the inflammatory, endothelial and thrombotic markers for arterial atherosclerotic disease in patients with prostate cancer with clinical indication for hormonal deprivation by drugs or surgical procedures